Lisa Wray, MD, is a board-certified pediatric hematologist-oncologist and an attending physician with the Cancer Center. She specializes in caring for children with cancer who are undergoing stem cell transplant or CAR T-cell therapy and pursues research with the goal of improving the results of those therapies.
For Dr. Wray, choosing a specialty in pediatric oncology came from a very personal experience – in college, a close childhood friend of hers died from cancer. “I wanted to care for others as I wish he had been cared for and advance care for pediatric oncology patients as a whole,” says Dr. Wray.
She is particularly excited by the progress the scientific community is making in treating childhood cancers, especially with stem cell transplant and CAR T-cell therapies. “I am fascinated by the science underlying these therapies which continues to rapidly evolve,” Dr. Wray says.
A scientist at heart, she doesn’t lose sight of the individual needs of each patient. “We have an incredible spectrum of people and services caring for every patient. We attempt to care for every patient and family as we would care for our own,” she says.
Dr. Wray earned her medical degree at Temple University School of Medicine and completed her pediatric residency, as well as a Hematology/Oncology fellowship at Children’s Hospital of Philadelphia. She is currently an assistant professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania.
Dr. Wray has published several papers and presented on various topics within oncology; she also served for four years on the Expert Review Board for KidsHealth.org. She is a long-standing member of the American Society for Transplantation and Cellular Therapy (ASTCT), American Society of Hematology (ASH) and the Children's Oncology Group (COG).
Dr. Wray’s current research focuses on improving stem cell transplant and CAR T-cell therapies. Within the realm of stem cell transplants, her work is aimed at optimizing nutrition for patients undergoing transplant. Regarding CAR T-cell therapy, she is interested by how the immune system is affected by, and recovers following, the therapy. “I’m excited to see CAR T-cell therapies be used to treat an ever-expanding range of diagnoses,” she says.
MD - Temple University School of Medicine, Philadelphia, PA
Pediatrics - Children's Hospital of Pittsburgh, Pittsburgh, PA
Pediatrics - Children's Hospital of Philadelphia, Philadelphia, PA
Hematology/Oncology - Children's Hospital of Philadelphia, Philadelphia, PA
Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Vujkovic M, Kershenbaum A, Wray L, McWilliams T, Cannon S, Devidas M, Stork L, Aplenc R.: Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952. Leukemia Research Reports 4(2): 47-50, Jul 2015. PMCID: PMC4621538
Wray L, Vujkovic M, McWilliams T, Cannon S, Devidas M, Stork L, Aplenc R.: TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer 61(11): 2086-8, Nov 2014. PMCID: PMC4283196
Smith K, Wray L, Klein-Cabral M, Schuchter L, Fox K, Glick J, DeMichele A.: Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clinical Breast Cancer 6(3): 260-9, Aug 2005.
DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B.: Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Research 63(22): 8051-6, Nov 2003.
Wray L, Miller E, Musheno R, Parikh S. The -ibs, -abs and Beyond: Immunotherapies for Pediatric Cancer Treatment and What They Mean for Pain and Symptom Management and Patient Prognosis. Oral presentation, Annual Assembly of Hospice and Palliative Care, Orlando, FL. March 2019.
Fraint E, Wray L, Miller E.: Emotional Reactions and Coping Mechanisms of Pediatric Residents to Patient Deaths. Poster presentation, American Academy of Pediatrics, Chicago, IL. September 2017.
2013 & 2014, Faculty Educator of the Month Award, selected by Pediatric Residents, Thomas Jefferson University Hospital
2010-2012, Hyundai Hope on Wheels Scholar Grant
2014-2018, Expert Review Board, KidsHealth.org
2009-present, Children's Oncology Group (COG)
2010-present, American Society for Blood and Marrow Transplantation (ASBMT)
2010-present, American Society of Hematology (ASH)
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.